Please use this identifier to cite or link to this item:
https://dspace.ctu.edu.vn/jspui/handle/123456789/5048
Title: | Microwave assisted synthesis and cytotoxic activity evaluations of new benzimidazole derivatives |
Authors: | Bùi, Thị Bửu Huê Hà, Thị Kim Quy Mai, Văn Hiếu Tran, Thi Loan Tran, Phuong Thao Pham, Canh Em Tu, Thi Kim Cuc Nguyen, Tram Yen Chau Vo, Duc Duy Oh, Won Keun |
Keywords: | 4-Oxo-4H-quinolizine Naphthalene Benzimidazole Stobbe condensation Microwave assisted organic synthesis Human breast cancer cell line |
Issue Date: | 2016 |
Series/Report no.: | Tetrahedron Letters;57 .- p.887–891 |
Abstract: | Twelve new 2-quinolizinylbenzimidazole and 2-naphthalylbenzimidazole derivatives with various 5- and 6-positioned substituents (aza, H, CH₃, Cl, NO₂, NH₂, OCH₃), have been synthesized in moderate to excellent yields via the condensation of 4-oxo-4H-quinolizinecarbaldehyde or naphthalenecarbaldehyde with substituted o-phenylenediamines, o-nitroaniline, and 2,3-pyridinediamine using sodium metabisulfite or sodium hydrosulfite under microwave irradiation. The new benzimidazole derivatives were screened for their cytotoxic activity against the human breast cancer cell line (MCF-7). The results showed on one hand that 2-(substituted quinolizinyl)-1H-benzimidazoles (12b–f) were less active (3–6 fold) than the positive control Tamoxifen (CC₅₀ = 6.52 μM), and on the other hand, among the 2-(substituted naphthalyl)-1H-benzimidazoles series (13a–f), compounds 6,7,8-trimethoxy-3-(5-chloro-1H-benzo[d]imidazol-2-yl)naphthalen-1-ol (13c) (CC₅₀ = 7.48 μM) and 6,7,8-trimethoxy-3-(5-methoxy-1H-benzo [d] imidazol-2-yl)naphthalen-1-ol (13f) (CC₅₀ = 6.43 μM) were found to be as active as Tamoxifen. |
URI: | http://localhost:8080//jspui/handle/123456789/5048 |
Appears in Collections: | Tạp chí quốc tế |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
_file_ | 541.97 kB | Adobe PDF | View/Open | |
Your IP: 3.137.159.163 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.